中源协和：拟收购子公司上海中源济生细胞科技有限公司股东所持25%股权

Group 1 - The core business revenue composition of Zhongyuan Qihua for the year 2024 is as follows: manufacturing accounts for 70.04%, services account for 27.21%, and other businesses account for 2.76% [1] - Zhongyuan Qihua announced on July 29 that it plans to acquire a 25% stake in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. from Shanghai Yanlin Biotechnology Co., Ltd. to enhance operational decision-making efficiency and increase investment in adult health cell storage business [3] - The total assessed value of 100% equity of Shanghai Zhongyuan Jisheng is approximately 15.2783 million yuan, with the agreed transaction price for the 25% stake being around 3.82 million yuan [3]